{"result": "(\"entity\"<|>ESPEN<|>ORGANIZATION<|>ESPEN is an organization that provides guidelines for nutrition in oncology patients, including those with head and neck cancers.)\n##\n(\"entity\"<|>GRP<|>ORGANIZATION<|>GRP refers to a prophylactic nutritional support system that was requested for the patient in the clinical case.)\n##\n(\"entity\"<|>DM<|>PERSON<|>DM refers to diabetes mellitus type 2, a condition that the patient in the clinical case is being treated for with insulin.)\n##\n(\"entity\"<|>NE<|>ORGANIZATION<|>NE refers to enteral nutrition, which is a method of delivering nutrition directly to the stomach or intestine.)\n##\n(\"entity\"<|>RT<|>EVENT<|>RT refers to radiotherapy, a treatment method that can cause complications such as mucositis in patients.)\n##\n(\"entity\"<|>QT<|>EVENT<|>QT refers to chemotherapy, another treatment method that can lead to complications in patients with head and neck cancers.)\n##\n(\"entity\"<|>CANCER<|>EVENT<|>Cancer, specifically head and neck cancer, requires significant nutritional management before, during, and after treatment.)\n##\n(\"entity\"<|>MUCOSITIS<|>EVENT<|>Mucositis is a complication associated with RT and QT that affects the oral cavity and can lead to difficulties in swallowing.)\n##\n(\"relationship\"<|>ESPEN<|>CANCER<|>ESPEN provides guidelines that are crucial for managing nutrition in patients with head and neck cancer<|>8)\n##\n(\"relationship\"<|>GRP<|>NE<|>The GRP was requested to provide nutritional support through enteral nutrition for the patient<|>7)\n##\n(\"relationship\"<|>DM<|>NE<|>The patient with diabetes mellitus type 2 requires specific nutritional formulas for enteral nutrition<|>6)\n##\n(\"relationship\"<|>RT<|>MUCOSITIS<|>Radiotherapy can lead to mucositis, which complicates the nutritional management of patients<|>9)\n##\n(\"relationship\"<|>QT<|>MUCOSITIS<|>Chemotherapy can also lead to mucositis, affecting the patient's ability to eat<|>9)\n##\n(\"relationship\"<|>CANCER<|>RT<|>Head and neck cancer treatment often involves radiotherapy<|>8)\n##\n(\"relationship\"<|>CANCER<|>QT<|>Head and neck cancer treatment often involves chemotherapy<|>8)\n##\n(\"relationship\"<|>NE<|>CANCER<|>Enteral nutrition is critical for patients with head and neck cancer to maintain nutritional status<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ancia hospitalaria8 . De hecho, la guía ESPEN de Nutrición en\nel Paciente Oncológico, incluye las neoplasias de cabeza y cuello dentro de las que\nse benefician de las fórmulas inmunomoduladoras, previo y posterior a la interven-\nción quirúrgica independientemente de su estado nutricional6 . Específicamente en\ncabeza y cuello, la arginina, en un metaanálisis9 , también ha demostrado que si\nse recibe peri/postoperatoriamente en NE reduce el número de fístulas y estancia\nhospitalaria, con influencia neutra en cuanto a infección de la herida quirúrgica.\nEn otros estudios10 , sin ser su objetivo principal, también se vio que administrada\nperioperatoriamente proporcionaba mayor supervivencia a largo plazo y tiempo sin\nrecurrencia, aunque estudios más firmes son necesarios para confirmar estas\npremisas.\n\n\n\n         La pauta de inmunonutrición que ha demostrado ser más costo efectiva y\npublicada en la literatura es11 :\n        •Predilección por la vía oral.\n        •Administrarla 5-7 días previo a la cirugía y 7 días después.\n        •En forma de SNO: 3 al día de 250 ml y en forma de NE: 1000-1500 ml diarios.\n\n\n\n         Al paciente del caso clínico se solicitó la colocación de una GRP profilácti-\nca, pero dado que no se contactó con la UN previo a la LT, sólo se pudo beneficiar\nde la inmunonutrición en el periodo post-quirúrgico, 7 días después de la cirugía.\nAdemás, es un paciente con DM tipo 2 en tratamiento con insulina, que también\nrequiere un abordaje específico dentro de las fórmulas de NE.\n\n\n\n                                                                                             143\n---\n              Cada vez con mayor evidencia y respaldo se sostiene que las fórmulas para\n     DM pueden mejorar el control glucémico a corto y largo plazo, a través de un menor\n     incremento de la glucemia post-prandial, de menores requerimientos de insulina y\n     en algunos casos, en mejoría de la hemoglobina glicosilada e incluso variabilidad\n     glucémica e hipoglucemias12 . Estas fórmulas, se caracterizan por aportar:\n             •Hidratos de carbono de bajo índice glucémico (almidón, fructosa, maltodex-\n             trinas).\n             •Ácidos grasos monoinsturados en mayores proporciones que el resto de\n             fórmulas.\n             •Alta proporción de fibra soluble (puede mejorar el perfil lipídico y glucémico).\n             •Micronutrientes antioxiantes.\n\n\n\n              En nuestro caso, tras pasar el periodo de la inmunonutrición de los 7 días,\n     donde es costo-efectiva, el paciente estuvo con NE con fórmula para DM, por los\n     beneficios que le puede aportar.\n\n\n\n              Otro aspecto clave en este espectro de pacientes, es el soporte nutricional y\n     seguimiento cuando se va a recibir RT y/o QT. Asociado ambas terapéuticas a muco-\n     sitis y en lo que ello repercute, disfagia y afagia, se aconseja casi un seguimiento\n     semanal para el soporte nutricional y prevenir la pérdida de peso, la monitorización\n     de la ingesta e impedir así la interrupción de los tratamientos. Es tan importante\n     este seguimiento que se aconseja visitar al paciente y supervisar mínimo hasta 3\n     meses tras el tratamiento2 .\n              Por último, no hay ninguna directriz marcada con respecto a cuando retirar\n     la GRP/PEG. El paciente del caso clínico recuperó totalmente la ingesta oral hasta\n     alcanzar requerimientos calóricos, además de corroborar que no iba a recibir ningún\n     tratamiento más que pudiese empeorar su estado nutricional. Una vez se retiró la\n     GRP, fue y es necesario mantener un seguimiento dietético y nutricional, pudiendo\n     dilatarlo más en el tiempo si el paciente está estable, para comprobar que se recu-\n     pera la deglución y la vía oral.\n\n\n\n     Conclusión\n              La patología oncológica de cabeza y cuello requiere de un importante abordaje\n     nutricional previo, durante y posterior al tratamiento, sea cual sea, desde cirugía, QT\n     y/o RT; por la repercusión que puede tener sobre la vía oral. En pacientes en los que\n     se va a prevenir una baja ingesta oral más allá de 10 días, es recomendable barajar la\n     gastrostomía para evitar una mayor pérdida de peso, interrupciones del tratamiento y\n     empeoramiento nutricional. Todo esto hace que el seguimiento y abordaje nutricional\n     sea un pilar fundamental en estos pacientes.\n\n\n\n144\n---\nBibliografía\n1. Bossola M. Nutritional interventions in head and neck\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}